Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The companies have entered into an agreement and partnership to offer biotech and pharmaceutical companies access to ApoCell’s ApoStream™ technology for the detection, isolation and enrichment of...
-
RUTHERFORD, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers...
-
The companies have entered into an agreement to offer biotech and pharmaceutical companies access to BARC’s network of global central laboratories covering 7 locations in 2 hemispheres in...
-
RUTHERFORD, N.J., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company"), a leader in enabling precision medicine for oncology through...
-
RUTHERFORD, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers...
-
Focus::Myeloid™ can help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently living with myeloid malignancies Focus::Myeloid™ is a...
-
Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015The Company’s Organic Growth Rate was 27% over Q1 and 18% over the Second Quarter of 2015, not...
-
RUTHERFORD, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
-
CGI will provide comprehensive, biomarker-based patient profiling using technologies such as next generation sequencing (NGS) to provide biomarker-driven insight regarding target...
-
Focus::CLL™ is the only CLIA-validated and NYS-approved NGS panel for CLL that offers information for patient risk stratification, disease management, and treatment selectionFocus::CLL™ addresses a...